1EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER:East clinical practice guidelines:Management of chronic hepatitis B[J]. J Hepatol,2009,50:227-242.
2POYNARD T,MASSARD J,RUDLER M,et al. Impact of inter- feron-alpha treatment on liver fibrosis in patients with chronic hepatitis B:An overview of published trials [J]. Gastroenterol Clin Biol,2009,27:33-35.
3BUSTER EHCJ,FLINK HJ,CAKAGLU Y,et al. Sustained HBeAg and HBsAg loss after long term follow-up of HbeAg positive patients treated with peginterferon-α-2b[J]. Gastroenterology, 2008,135:459-467.
4MANENSIS EK,HADZIYANNNIS ES,ANGELOPOULOU OP, et al. Prediction of treatmentrelated HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels[J]. Antivir Ther,2007,12:73-82.
5GISH RG,LAU DT,SCHMID P,et al. A pilot study of extended treatment duration peginterferon alfa-2a for patients with hepatitis B e antigen negative chronic hepatitis B[J]. Am J Gastroenterol, 2007,102:2718-2723.
7CAMMA C,DI BONA D,SCHEPIS F,et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data[J]. Hepatology,2004, 39(2):333-342.
